RDY
Dr. Reddy's Laboratories Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IN
$14.77
+3.29%Year over year
Reported trailing growth
- Revenue
- -3.1%
- EBITDA
- -45.2%
- EBIT
- -58.6%
- EPS
- -51.7%
- Free cash flow
- -35.0%
- Operating cash flow
- -48.8%
Forward estimates
Based on analyst estimates
- Revenue
- +15.5%
- EBITDA
- +57.7%
- EPS
- +53.9%
Three-year CAGR
- Revenue
- +12.9%
- EBITDA
- +3.8%
- EBIT
- -5.1%
- Net income
- +0.0%
- EPS
- -0.2%
- Free cash flow
- -7.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026